Targeting Mnks for cancer therapy

Jinqiang Hou, Frankie Lam, Christopher Proud, Shudong Wang

Research output: Contribution to journalReview article

103 Citations (Scopus)

Abstract

Deregulation of protein synthesis is a common event in human cancer and a key player in translational control is eIF4E. Elevated expression levels of eIF4E promote cancer development and progression. Recent findings suggest that eIF4E activity is a key determinant of the PI3K/Akt/mTOR and Ras/Raf/MEK/ERK mediated tumorigenic activity and targeting eIF4E should have a major impact on these pathways in human cancer. The function of eIF4E is modulated through phosphorylation of a conserved serine (Ser209) by Mnk1 and Mnk2 downstream of ERK. While the phosphorylation event is necessary for oncogenic transformation, it seems to be dispensable for normal development. Hence, pharmacologic Mnk inhibitors may provide non-toxic and effective anti-cancer strategy. Strong circumstantial evidence indicates that Mnk inhibition presents attractive therapeutic potential, but the lack of selective Mnk inhibitors has so far confounded pharmacological target validation and clinical development.

LanguageEnglish
Pages118-131
Number of pages14
JournalOncotarget
Volume3
Issue number2
DOIs
Publication statusPublished - 1 Jan 2012
Externally publishedYes

Keywords

  • Akt
  • MAPK
  • Mnk
  • Mnk inhibitors
  • Pi3K
  • Raf
  • Ras
  • Structure based drug design
  • Targeted cancer therapy
  • eIF4E
  • mTOR

ASJC Scopus subject areas

  • Oncology

Cite this

Hou, Jinqiang ; Lam, Frankie ; Proud, Christopher ; Wang, Shudong. / Targeting Mnks for cancer therapy. In: Oncotarget. 2012 ; Vol. 3, No. 2. pp. 118-131.
@article{fabb3b75935f44bb907ed24d8b9c6137,
title = "Targeting Mnks for cancer therapy",
abstract = "Deregulation of protein synthesis is a common event in human cancer and a key player in translational control is eIF4E. Elevated expression levels of eIF4E promote cancer development and progression. Recent findings suggest that eIF4E activity is a key determinant of the PI3K/Akt/mTOR and Ras/Raf/MEK/ERK mediated tumorigenic activity and targeting eIF4E should have a major impact on these pathways in human cancer. The function of eIF4E is modulated through phosphorylation of a conserved serine (Ser209) by Mnk1 and Mnk2 downstream of ERK. While the phosphorylation event is necessary for oncogenic transformation, it seems to be dispensable for normal development. Hence, pharmacologic Mnk inhibitors may provide non-toxic and effective anti-cancer strategy. Strong circumstantial evidence indicates that Mnk inhibition presents attractive therapeutic potential, but the lack of selective Mnk inhibitors has so far confounded pharmacological target validation and clinical development.",
keywords = "Akt, MAPK, Mnk, Mnk inhibitors, Pi3K, Raf, Ras, Structure based drug design, Targeted cancer therapy, eIF4E, mTOR",
author = "Jinqiang Hou and Frankie Lam and Christopher Proud and Shudong Wang",
year = "2012",
month = "1",
day = "1",
doi = "10.18632/oncotarget.453",
language = "English",
volume = "3",
pages = "118--131",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "2",

}

Hou, J, Lam, F, Proud, C & Wang, S 2012, 'Targeting Mnks for cancer therapy', Oncotarget, vol. 3, no. 2, pp. 118-131. https://doi.org/10.18632/oncotarget.453

Targeting Mnks for cancer therapy. / Hou, Jinqiang; Lam, Frankie; Proud, Christopher; Wang, Shudong.

In: Oncotarget, Vol. 3, No. 2, 01.01.2012, p. 118-131.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Targeting Mnks for cancer therapy

AU - Hou, Jinqiang

AU - Lam, Frankie

AU - Proud, Christopher

AU - Wang, Shudong

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Deregulation of protein synthesis is a common event in human cancer and a key player in translational control is eIF4E. Elevated expression levels of eIF4E promote cancer development and progression. Recent findings suggest that eIF4E activity is a key determinant of the PI3K/Akt/mTOR and Ras/Raf/MEK/ERK mediated tumorigenic activity and targeting eIF4E should have a major impact on these pathways in human cancer. The function of eIF4E is modulated through phosphorylation of a conserved serine (Ser209) by Mnk1 and Mnk2 downstream of ERK. While the phosphorylation event is necessary for oncogenic transformation, it seems to be dispensable for normal development. Hence, pharmacologic Mnk inhibitors may provide non-toxic and effective anti-cancer strategy. Strong circumstantial evidence indicates that Mnk inhibition presents attractive therapeutic potential, but the lack of selective Mnk inhibitors has so far confounded pharmacological target validation and clinical development.

AB - Deregulation of protein synthesis is a common event in human cancer and a key player in translational control is eIF4E. Elevated expression levels of eIF4E promote cancer development and progression. Recent findings suggest that eIF4E activity is a key determinant of the PI3K/Akt/mTOR and Ras/Raf/MEK/ERK mediated tumorigenic activity and targeting eIF4E should have a major impact on these pathways in human cancer. The function of eIF4E is modulated through phosphorylation of a conserved serine (Ser209) by Mnk1 and Mnk2 downstream of ERK. While the phosphorylation event is necessary for oncogenic transformation, it seems to be dispensable for normal development. Hence, pharmacologic Mnk inhibitors may provide non-toxic and effective anti-cancer strategy. Strong circumstantial evidence indicates that Mnk inhibition presents attractive therapeutic potential, but the lack of selective Mnk inhibitors has so far confounded pharmacological target validation and clinical development.

KW - Akt

KW - MAPK

KW - Mnk

KW - Mnk inhibitors

KW - Pi3K

KW - Raf

KW - Ras

KW - Structure based drug design

KW - Targeted cancer therapy

KW - eIF4E

KW - mTOR

UR - http://www.scopus.com/inward/record.url?scp=84863803532&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.453

DO - 10.18632/oncotarget.453

M3 - Review article

VL - 3

SP - 118

EP - 131

JO - Oncotarget

T2 - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 2

ER -